Slide 1: First Quarter 2017 Results
K Pharm First Quarter 2017 Results
Slide 2: Cautionary Note Regarding Presentation Information
Cautionary Note Regarding Presentation Information This presentation contains forward-looking statements, including statements about our plans to develop and commercialize our product candidates, our planned clinical trials for our prodrug product candidates, the timing of and our ability to obtain
Slide 3: First Quarter 2017 — Conference Call Participants
First Quarter 2017 — Conference Call Participants + Travis Mickle, Ph.D. - President & Chief Executive Officer * Dan Cohen, M.A.L.S.— EVP, Government & Public Relations + R. LaDuane Clifton, CPA - Chief Financial Officer, Secretary & Treasurer
Slide 4: Q1 2017 & Recent Updates
Q1 2017 & Recent Updates Clinical & Regulatory Reported Positive Data from Phase 1 Proof-of-Concept Intranasal Pharmacokinetic Trial of KP511 Announced Additional U.S. Patent Protection for KP511 and KP201/IR Presented Clinical Data for KP201/IR and KP511 atAmerican Academy of Pain Medicine’s Annual
Slide 5: KemPharm Overview
KemPharm Overview + Specialty pharmaceutical company discovering and developing novel prodrugs « Leveraging our LAT Platform Technology to improve the attributes of approved drugsin large markets + Building a pipeline of product candidates for the treatment of ADHD, pain and CNS disorders + Potentia
Slide 6: Ligand Activated Therapy (LAT) Platform Technology
Ligand Activated Therapy (LAT) Platform Technology ax ©” aD ax © ( ( —_ —— Approved Drug with Ligand Prodrugwith Cleaved Drug through Sub-Optimal Improved Attributes Human Metabolic Properties Process 1) Select FDA-approved and widely prescribed drug for improvement 2) Chemically modify using a liga
Slide 7: KP415 Product Overview
KP415 Product Overview Extended release prodrug of methylphenidate Phase 1 PoC Data: Earlier d- MPH exposure followed by a slower extended release of d-MPH relative to Concerta Data from clinical studies suggests KP415 could allow for once-daily dosing with a potentially improved onset of action Bra
Slide 8: KP201/IR (APAP-free)
KP201/IR (APAP-free) Product Overview Development Timeline + IR formulation of benzhydrocodone v KP201/IR IND accepted by FDA on combined with an aversive formulation Potentially the first IR hydrocodone- related product without APAP in the U.S. Fast Track designation KP201 Intranasal PK Trial (A03)
Slide 9: Formal Dispute Resolution Request (FDRR) Update
Formal Dispute Resolution Request (FDRR) Update *« KemPharm filed an appeal of the CRL for Apadaz™ through the initiation of the FDRR process (announced on Nov. 3, 2016) + FDRR process is designed to provide pathway by which applicants seek to resolve scientific and/or medical policy disputes that c
Slide 10: Norco vs. Apadaz — Drug Liking
Norco vs. Apadaz — Drug Liking Norco 100 4 -@- 2 Tablets - Snorted 90 4 —e-2 Tablets - Oral Mean+SEDrug 80 + Liking 70 60 50 100 4 90 4 80 4 Apadaz -@- 2 Tablets - Snorted —e@-—2 Tablets - Oral Time (hours) Time (hours) ‘Study A02: Intranasal HAP Study (N=42)
Slide 11: KP511/ER and KP511/IR
KP511/ER and KP511/IR Product Overview Development Timeline + Prodrug of hydromorphone v_ Data from intranasal HAL studies of KP511 API announced Jan. 9, 2017 + Being developed as ER and IR formulations + Investigation anticipated into KP511’s potential to limit oral abuse + Demonstrated comparable
Slide 12: Q1 2017 Financial Update
Q1 2017 Financial Update * Q1 2017 net loss of $16.3M, or $1.11 per basic and diluted share, vs. Q1 2016 net loss of $2.9M, or $0.20 per basic and diluted share Net loss for Q1 2017 increased primarily due to non-cash fair value adjustments to our derivative and warrant liabilities, which shifted fr
Slide 13: KemPharm Expected Milestones
KemPharm Expected Milestones Product KP415 KP415 2017 KP415 KP201/IR KP201/IR KP415 2018 KP415 KP201/IR 2019 | KP511/ER & KP511/IR Eve Initiate Additional PK Studies (1H) Report Additional PK Data (2H) Initiate Pivotal Efficacy Trial (2H) Human Clinical Trial Initiation (Mid) Intranasal HAL Study Da
Slide 14: First Quarter 2017 Results
K Pharm First Quarter 2017 Results